An Open-label, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of GSK2118436 in Japanese Subjects With BRAF V600 Mutation Positive Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2015
At a glance
- Drugs Dabrafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 13 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 19 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.